<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In France, more than 80% of children with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> or Burkitt's <z:hpo ids='HP_0001909'>leukemia</z:hpo> (ALL3) are now cured with the LMB (B-cell non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>) protocols of the Société Française d'Oncologie Pédiatrique, but so far, poor results have been obtained in the few adult studies available </plain></SENT>
<SENT sid="1" pm="."><plain>We have analyzed the experience with LMB protocols in adult patients </plain></SENT>
<SENT sid="2" pm="."><plain>This retrospective study involved 65 adult patients with small noncleaved cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> or ALL3 treated with the LMB protocols </plain></SENT>
<SENT sid="3" pm="."><plain>They were 17 to 65 years old and not previously treated </plain></SENT>
<SENT sid="4" pm="."><plain>Human <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> virus-infected patients were excluded </plain></SENT>
<SENT sid="5" pm="."><plain>The diagnoses were made between September 1984 and August 1991 </plain></SENT>
<SENT sid="6" pm="."><plain>According to the Murphy classification, 12 patients (18%) had stage I or II disease, 25 (38%), stage III disease; 4 (6%), stage IV disease; and 24 (37%), ALL3 (&gt; or = 25% blasts) </plain></SENT>
<SENT sid="7" pm="."><plain>According to the Ann Arbor classification, 9 patients had stage I disease; 8 patients, stage II; 5 patients, stage III; 21 patients, stage IV disease; and 22 patients, ALL (&gt; or = 30% blasts) </plain></SENT>
<SENT sid="8" pm="."><plain>Twelve patients had central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) involvement before treatment </plain></SENT>
<SENT sid="9" pm="."><plain>Thirty-nine patients were treated according to the LMB 84 protocol scheme; 14 according to the LMB 86 protocol, and 12 patients received the LMB 84 induction courses followed by the LMB 86 consolidation courses </plain></SENT>
<SENT sid="10" pm="."><plain>Three patients underwent bone marrow transplantation (BMT) while in second complete remission (CR) and 3 others had refractory disease </plain></SENT>
<SENT sid="11" pm="."><plain>There were some protocol violations caused by empirical medical decisions: local irradiation was performed in 4 patients, 2 patients received prophylactic radiation to the brain that was not specified in the protocol, 13 patients underwent BMT in first CR, and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> doses were modified in 10 patients </plain></SENT>
<SENT sid="12" pm="."><plain>Fifty-eight patients (89%) achieved a CR </plain></SENT>
<SENT sid="13" pm="."><plain>There were four (6%) primary induction treatment failures, and three (4%) early treatment-related <z:hpo ids='HP_0011420'>deaths</z:hpo> </plain></SENT>
<SENT sid="14" pm="."><plain>Eight patients relapsed between 2 and 30 months after CR (median, 4.7 months) </plain></SENT>
<SENT sid="15" pm="."><plain>Forty-seven patients are alive in CR (45 first CR, 2 second CR) with a median follow-up of 57 months (24 to 93 months) </plain></SENT>
<SENT sid="16" pm="."><plain>There were five toxicity-related <z:hpo ids='HP_0011420'>deaths</z:hpo> among patients in CR including four BMT-related <z:hpo ids='HP_0011420'>deaths</z:hpo> and five <z:hpo ids='HP_0011420'>deaths</z:hpo> caused by refractory relapses </plain></SENT>
<SENT sid="17" pm="."><plain>One patient died in CR at 62 months of <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> </plain></SENT>
<SENT sid="18" pm="."><plain>The 3-year overall survival rate is 74% (SE = 5) </plain></SENT>
<SENT sid="19" pm="."><plain>According to the stages in the Murphy classification, the 3-year survival rates are stages I and II, 100%; stage III, 80% (SE = 7); and stage IV and ALL, 57% (SE = 8) </plain></SENT>
<SENT sid="20" pm="."><plain>Seven of 12 patients with initial <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> disease are alive with a median survival of 56 months.(ABSTRACT TRUNCATED AT 400 WORDS) </plain></SENT>
</text></document>